vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and FARMERS NATIONAL BANC CORP (FMNB). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $71.5M, roughly 1.3× FARMERS NATIONAL BANC CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs 20.5%, a 7.9% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 3.2%). FARMERS NATIONAL BANC CORP produced more free cash flow last quarter ($52.2M vs $32.6M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 6.2%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Farmers National Banc Corp (OH) is a regional financial holding company based in Ohio, the United States. It offers full-spectrum retail and commercial banking products, wealth management solutions, and insurance services, primarily catering to individual consumers, small and medium-sized enterprises, and local community clients in Ohio and adjacent Midwestern U.S. regions.
DVAX vs FMNB — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $71.5M |
| Net Profit | $26.9M | $14.6M |
| Gross Margin | — | — |
| Operating Margin | 22.4% | 24.8% |
| Net Margin | 28.4% | 20.5% |
| Revenue YoY | 17.7% | 3.2% |
| Net Profit YoY | 53.0% | 1.7% |
| EPS (diluted) | $0.21 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $71.5M | ||
| Q3 25 | $94.9M | $70.8M | ||
| Q2 25 | $95.4M | $69.8M | ||
| Q1 25 | $68.2M | $67.8M | ||
| Q4 24 | $72.0M | $69.3M | ||
| Q3 24 | $80.6M | $70.3M | ||
| Q2 24 | $73.8M | $66.5M | ||
| Q1 24 | $50.8M | $63.4M |
| Q4 25 | — | $14.6M | ||
| Q3 25 | $26.9M | $12.5M | ||
| Q2 25 | $18.7M | $13.9M | ||
| Q1 25 | $-96.1M | $13.6M | ||
| Q4 24 | $7.0M | $14.4M | ||
| Q3 24 | $17.6M | $8.5M | ||
| Q2 24 | $11.4M | $11.8M | ||
| Q1 24 | $-8.7M | $11.2M |
| Q4 25 | — | 24.8% | ||
| Q3 25 | 22.4% | 20.7% | ||
| Q2 25 | 15.1% | 23.4% | ||
| Q1 25 | -34.7% | 24.1% | ||
| Q4 24 | -2.3% | 25.5% | ||
| Q3 24 | 12.5% | 14.4% | ||
| Q2 24 | 7.0% | 21.3% | ||
| Q1 24 | -35.0% | 21.2% |
| Q4 25 | — | 20.5% | ||
| Q3 25 | 28.4% | 17.6% | ||
| Q2 25 | 19.6% | 19.9% | ||
| Q1 25 | -141.0% | 20.0% | ||
| Q4 24 | 9.8% | 20.8% | ||
| Q3 24 | 21.8% | 12.1% | ||
| Q2 24 | 15.4% | 17.7% | ||
| Q1 24 | -17.2% | 17.7% |
| Q4 25 | — | $0.39 | ||
| Q3 25 | $0.21 | $0.33 | ||
| Q2 25 | $0.14 | $0.37 | ||
| Q1 25 | $-0.77 | $0.36 | ||
| Q4 24 | $0.07 | $0.38 | ||
| Q3 24 | $0.12 | $0.23 | ||
| Q2 24 | $0.08 | $0.31 | ||
| Q1 24 | $-0.07 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | — |
| Total DebtLower is stronger | — | $86.7M |
| Stockholders' EquityBook value | $534.1M | $485.7M |
| Total Assets | $946.5M | $5.2B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $160.2M | — | ||
| Q2 25 | $99.1M | — | ||
| Q1 25 | $51.7M | — | ||
| Q4 24 | $95.9M | — | ||
| Q3 24 | $119.3M | — | ||
| Q2 24 | $112.5M | — | ||
| Q1 24 | $132.0M | — |
| Q4 25 | — | $86.7M | ||
| Q3 25 | — | $86.6M | ||
| Q2 25 | — | $86.4M | ||
| Q1 25 | — | $86.3M | ||
| Q4 24 | — | $86.2M | ||
| Q3 24 | — | $86.0M | ||
| Q2 24 | — | $88.9M | ||
| Q1 24 | — | $88.8M |
| Q4 25 | — | $485.7M | ||
| Q3 25 | $534.1M | $465.9M | ||
| Q2 25 | $494.2M | $437.7M | ||
| Q1 25 | $530.9M | $429.1M | ||
| Q4 24 | $596.8M | $406.0M | ||
| Q3 24 | $681.4M | $439.7M | ||
| Q2 24 | $642.8M | $396.7M | ||
| Q1 24 | $618.5M | $397.0M |
| Q4 25 | — | $5.2B | ||
| Q3 25 | $946.5M | $5.2B | ||
| Q2 25 | $918.4M | $5.2B | ||
| Q1 25 | $945.9M | $5.2B | ||
| Q4 24 | $986.3M | $5.1B | ||
| Q3 24 | $1.1B | $5.2B | ||
| Q2 24 | $1.0B | $5.2B | ||
| Q1 24 | $986.6M | $5.1B |
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $60.0M |
| Free Cash FlowOCF − Capex | $32.6M | $52.2M |
| FCF MarginFCF / Revenue | 34.4% | 73.0% |
| Capex IntensityCapex / Revenue | 1.3% | 11.0% |
| Cash ConversionOCF / Net Profit | 1.26× | 4.10× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $85.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $60.0M | ||
| Q3 25 | $33.8M | $10.7M | ||
| Q2 25 | $23.4M | $14.0M | ||
| Q1 25 | $-19.6M | $15.7M | ||
| Q4 24 | $53.0M | $66.6M | ||
| Q3 24 | $19.5M | $23.9M | ||
| Q2 24 | $10.7M | $16.6M | ||
| Q1 24 | $-16.7M | $13.7M |
| Q4 25 | — | $52.2M | ||
| Q3 25 | $32.6M | $9.0M | ||
| Q2 25 | $22.0M | $12.4M | ||
| Q1 25 | $-23.6M | $12.2M | ||
| Q4 24 | $49.5M | $54.9M | ||
| Q3 24 | $18.1M | $20.4M | ||
| Q2 24 | $9.9M | $14.4M | ||
| Q1 24 | $-17.4M | $12.2M |
| Q4 25 | — | 73.0% | ||
| Q3 25 | 34.4% | 12.8% | ||
| Q2 25 | 23.0% | 17.8% | ||
| Q1 25 | -34.6% | 18.0% | ||
| Q4 24 | 68.8% | 79.2% | ||
| Q3 24 | 22.5% | 29.1% | ||
| Q2 24 | 13.5% | 21.6% | ||
| Q1 24 | -34.3% | 19.2% |
| Q4 25 | — | 11.0% | ||
| Q3 25 | 1.3% | 2.4% | ||
| Q2 25 | 1.5% | 2.3% | ||
| Q1 25 | 5.8% | 5.2% | ||
| Q4 24 | 4.8% | 16.9% | ||
| Q3 24 | 1.7% | 4.9% | ||
| Q2 24 | 1.1% | 3.3% | ||
| Q1 24 | 1.5% | 2.4% |
| Q4 25 | — | 4.10× | ||
| Q3 25 | 1.26× | 0.86× | ||
| Q2 25 | 1.25× | 1.01× | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | 7.52× | 4.63× | ||
| Q3 24 | 1.11× | 2.80× | ||
| Q2 24 | 0.94× | 1.41× | ||
| Q1 24 | — | 1.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
FMNB
Segment breakdown not available.
